Research
library

A Certificate of Analysis proves what’s actually in a vial. But it’s only worth something if you know how to read it — and how to confirm it hasn’t been faked. This covers both.

What a COA actually is

A COA is a report from an analytical laboratory documenting the testing performed on a specific batch. A legitimate COA is tied to a single lot number, dated, and issued by a named third-party lab — not the seller. A “COA” produced by the seller themselves isn’t independent verification; it’s self-certification, which carries far less weight.

Reading each section

HPLC purity assay. High-performance liquid chromatography separates the compound from impurities and measures what percentage of the sample is the target molecule. 99.6% means 99.6% of the peptide content is the intended compound. For research peptides, ≥98% is the common benchmark.

FTIR identification. Fourier-transform infrared spectroscopy confirms the identity of the compound by matching its molecular fingerprint against the expected spectrum. Purity tells you how clean it is; FTIR tells you it’s the right molecule. A sample can be 99% pure but be the wrong compound entirely.

Potency assay. Measures how much active compound is present versus what the label claims. A 10mg vial showing “10mg (100.2%)” contains essentially the labelled amount. Results between 90–110% of label are within standard acceptable range.

Mass / appearance / excipient ratio. Supporting checks: recorded total mass, visual description (e.g. white powder), and the ratio of peptide to excipients. These confirm the physical sample matches expectation.

The lot number is the link

The single most important field is the lot number. It connects the physical vial in your hand to the specific COA. If the lot number on your vial doesn’t match the COA, the certificate doesn’t apply to your product — no matter how good the numbers look. Always check they match.

How to verify a BTLabs COA

A COA can be read — but how do you know it’s genuine and not edited? This is where independent verification matters. BTLabs operates a verification system that checks a certificate against their own database in real time:

1. Go to verify.btlabtesting.com.
2. Enter the COA number for the product (shown on each certificate listing).
3. The system checks the number against BTLabs’ records and returns the matching certificate if it exists.

Because verification runs against the lab’s own database — not the seller’s — a fabricated or altered certificate won’t resolve. That’s the difference between seeing a COA and verifying one. Anyone can show you a document; only a real, lab-issued COA passes independent verification.

Red flags to watch for

• No lot number, or one that doesn’t match the vial.
• A “COA” issued by the seller rather than an independent lab.
• No verification path — you can see a document but can’t confirm it with the lab.
• Missing FTIR identity confirmation (purity alone doesn’t prove the compound is correct).
• Results that can’t be cross-checked against a named, contactable laboratory.

Body Protection Compound-157 is a synthetic pentadecapeptide of 15 amino acids, with a sequence derived from a segment of the human gastric juice protein BPC. It does not occur freely in nature in this exact form.

Molecular structure

BPC-157 has the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a molecular weight of ~1419.5 Da, and the formula C₆₂H₉₈N₁₆O₂₂. Its proline-rich central region confers notable resistance to proteolytic degradation in gastric acid.

Nitric oxide & vascular signalling

Preclinical studies indicate BPC-157 modulates the nitric oxide system, upregulating eNOS expression, and has been documented to upregulate VEGFR2 — the primary signalling receptor for vascular endothelial growth factor — in endothelial cell models.

FAK & growth factor pathways

Published research documents BPC-157 activation of focal adhesion kinase (FAK) and paxillin — pathways integral to cell migration and survival. FAK activation signals downstream through PI3K/Akt and MAPK/ERK.

Research status

As of 2026, BPC-157 has not completed human clinical trials and is not approved by the FDA or EMA. Mechanistic data derives from in vitro and rodent models. It is classified as a research compound.

Retatrutide (LY3437943) is a synthetic acylated peptide and triple agonist designed to simultaneously activate GLP-1R, GIPR, and GCGR.

Molecular structure

A 36-amino acid peptide analogue related to glucagon. A C18 fatty diacid moiety confers albumin binding, extending half-life to ~1 week and enabling once-weekly subcutaneous dosing.

GLP-1 & GIP receptor agonism

GLP-1R agonism stimulates glucose-dependent insulin secretion, slows gastric emptying, and activates hypothalamic satiety circuits. GIPR agonism amplifies insulin secretion and modulates adipocyte lipid metabolism; together they produce synergistic effects exceeding either pathway alone.

Glucagon receptor agonism

GCGR agonism distinguishes triple agonists from dual therapies — it increases hepatic fatty acid oxidation and elevates basal metabolic rate via thermogenic mechanisms, with concurrent GLP-1R/GIPR activation counteracting GCGR-mediated hyperglycaemia.

Research status

As of 2026, retatrutide has completed Phase 2 and entered Phase 3. It is not approved by the FDA or EMA. Phase 2 results were published in NEJM in 2023.

MOTS-c is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Its 2015 discovery showed mitochondria produce bioactive peptides capable of nuclear signalling.

Genomic origin

Encoded by an open reading frame within the mitochondrial 12S rRNA gene. Human sequence: MRWQEMGYFYRKKQEGYNLHRR. It belongs to the mitochondrial-derived peptide (MDP) family alongside humanin.

Nuclear translocation & AMPK

Under metabolic stress, MOTS-c translocates to the nucleus and interacts with antioxidant response element (ARE) regions and Nrf2. It activates AMPK in skeletal muscle and adipose tissue, partly via ATIC inhibition leading to AICAR accumulation.

Glutathione (GSH; γ-L-glutamyl-L-cysteinylglycine) is a tripeptide and the most abundant non-protein thiol in mammalian cells, at 1–10 mM intracellular concentrations.

Biosynthesis

Synthesised in two ATP-dependent reactions. Glutamate-cysteine ligase (the rate-limiting enzyme) produces γ-glutamylcysteine; glutathione synthetase then adds glycine.

Redox chemistry & GPx system

The cysteine thiol donates electrons to reactive oxygen species, oxidising to GSSG, which glutathione reductase regenerates. GSH is the primary electron donor for glutathione peroxidase (GPx) enzymes, of which GPx4 uniquely reduces phospholipid hydroperoxides — critical for preventing ferroptosis.

Xenobiotic metabolism

Glutathione S-transferases conjugate GSH to electrophilic substrates and lipid peroxidation products, aiding excretion. Protein S-glutathionylation also acts as a redox-sensitive regulatory switch.

GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide-copper complex first isolated from human plasma albumin in 1973.

Structure & copper binding

GHK (MW 340.38) coordinates Cu²⁺ through a square planar geometry, conferring exceptional selectivity for copper with a stability constant log K ≈ 16.4.

Gene expression modulation

Connectivity Map analysis identified GHK as a modulator of over 4,000 human gene pathways, with documented effects on collagen synthesis genes (COL1A1, COL1A2) and antioxidant enzyme expression via ARE/Nrf2 pathways.

Copper chaperoning

GHK-Cu delivers Cu²⁺ to cuproenzymes including cytochrome c oxidase, Cu/Zn-SOD, lysyl oxidase, and ceruloplasmin, with uptake via the CTR1 transporter.

Cagrilintide (AM833) is a long-acting acylated analogue of human amylin, a 37-amino acid peptide co-secreted with insulin, designed for once-weekly subcutaneous dosing.

Endogenous amylin biology

Amylin (islet amyloid polypeptide) is co-secreted with insulin from pancreatic β-cells at a ~1:10–20 molar ratio. Native amylin has a half-life of ~15 minutes due to rapid clearance and aggregation.

Amylin receptor pharmacology

Amylin receptors (AMY1–3) are heterodimers of the calcitonin receptor paired with RAMP1/2/3 proteins. They are class B GPCRs coupling to Gs, elevating cAMP. AMY1 shows highest affinity. Receptors are dense in the area postrema, NTS, and hypothalamus.

Structural modifications

Cagrilintide incorporates substitutions reducing amyloid aggregation plus a fatty acid acyl chain for albumin binding, extending half-life from minutes to ~7 days.

Research status

As of 2026, cagrilintide and CagriSema have completed Phase 3. Neither is approved by the FDA or EMA. It remains a research compound.

Semax and Selank are synthetic neuropeptides developed in Russia, both derived from endogenous peptide sequences with a shared design approach.

Semax — structure

A heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) analogue of the ACTH(4-10) fragment, with a C-terminal Pro-Gly-Pro added for stability. MW: 813.94 g/mol.

Semax — BDNF & neurotrophin signalling

The most documented mechanism is upregulation of BDNF and its receptor TrkB, central to synaptic plasticity and neuronal survival. TrkB activation engages MAPK/ERK, PI3K/Akt, and PLCγ. Semax also upregulates VEGF in CNS tissue and modulates dopamine and serotonin metabolism.

Selank — structure

A heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) analogue of the immunomodulatory peptide tuftsin, with Pro-Gly-Pro added for stability. MW: 751.86 g/mol.

Selank — GABAergic & enkephalin systems

Selank’s most characterised mechanism is interaction with GABA-A receptors, proposed as a positive allosteric modulator at the benzodiazepine site. It also inhibits enkephalin-degrading enzymes, increasing endogenous opioid peptide availability, modulates serotonin turnover, and upregulates BDNF.

Research status

Both are registered pharmaceuticals in Russia but are not approved by the FDA or EMA, and neither has completed Western-standard randomised controlled trials. Both are classified as research compounds outside Russia.